Medical Device and Wound Care News and Analysis Blog

Reimbursement, Evidence and the Role of Collagen in Skin Substitutes: SAWC Fall 2026

Written by Kris Flinn | 11/17/26, 2:30 PM

 At SAWC Fall 2026, SmartTRAK interviews EnColl’s Murugan Gunasekaran on how new skin substitute reimbursement caps are reshaping patient care. 

Murugan Gunasekaran, vice president, sales and marketing at EnColl, discusses the shifting reimbursement landscape for skin substitutes and its impact on chronic wound care in an interview with SmartTRAK’s Kris Flinn at the Symposium on Advanced Wound Care (SAWC) Fall 2026 meeting held recently in Las Vegas. The two explore how payment restructuring and price caps are reshaping patient access across practice settings, the emerging role of biomaterial science in product evaluation, and how EnColl’s bioengineered collagen skin substitute, HELICOLL, advances tissue regeneration, promoting faster healing and cost-effective patient care.

To listen to the interview, click on the following video (6:39 min). A link to download a complete transcript of the interview is also provided below. 


I
nterview Transcript​

SmartTRAK: This is Kris Flinn with SmartTRAK. I'm here at SAWC Fall 2026 in Las Vegas, Nevada. I'm joined today by Murugan from EnColl to talk about HELICOLL and how it's being used on chronic wounds. Murugan, thank you for joining me today.

Murugan Gunasekaran: Thank you, Kris.

So Murugan, we're looking at a very uncertain future for the reimbursement landscape and skin substitutes. The CMS has given guidance previously that there may be splits by different regulatory status and historically, clinical evidence and real world evidence have been the drivers of looking at the value given to different products and product types.

MG: Absolutely.

Do you believe this is what will be used in the future? And if not, what else do you think might be taking place?

MG: Yes, I think you touched on two important things. Right? So clinical evidence and real world evidence are very important. They're able to see, hey, how are these products being used on a variety of different patients, including diabetic patients, non-diabetic patients, how old some of these patients are, the different racial backgrounds some of these patients are, the demographics, these are all very important.

Now there's a third aspect I think that's going to be really important coming into 2028* and beyond, and that's actually the ...

Click the button below to download and read the full transcript of SmartTRAK Wound GM Kris Flinn’s interview with EnColl’s Murugan Gunasekaran discussing how new skin substitute reimbursement caps are reshaping patient care.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.